Pfizer Gets CDSCO Panel Nod To study Anti-cancer Drug Disitamab vedotin
New Delhi: Pfizer has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the trial of the anti-cancer drug Disitamab vedotin.
However, this approval is subject to the condition to include more geographically distributed government sites in the study and the principal investigator (PI) should be a medical oncologist.
This came after the firm presented phase 3 clinical study protocol no: C5731001 amendment 03 dated 03 December-2024.
Disitamab vedotin (DV, also known as RC48) is an antibody-drug conjugate (ADC) used to treat HER2-positive solid tumors, particularly gastric cancer and urothelial cancer. It consists of a monoclonal antibody targeting HER2, linked to the cytotoxic agent monomethyl auristatin E (MMAE), which is delivered to tumor cells.
Disitamab Vedotin (also known as RC48) is classified as an antibody-drug conjugate (ADC). ADCs are a type of targeted cancer therapy that combines a monoclonal antibody with a cytotoxic drug.
At the recent SEC meeting for oncology held on 11th March 2025, the expert panel reviewed phase 3 clinical study protocol no. C5731001 amendment 03 dated 03-December-2024.
After detailed deliberation, the committee recommended the grant of permission to conduct the trial as presented by the firm with the following condition:
1. More geographically distributed government sites shall be included in the study.
2. The principal investigator (PI) shall be a medical oncologist only.
Also Read: Hetero Labs gets CDSCO Panel nod to study Tegoprazan tablet 50 mg
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.